EAN 2026: Real-world data supports safety and efficacy of AbbVie’s Vyalev in Parkinson’s
AbbVie's ROSSINI (NCT06107426) study of its Parkinson's disease combination, Vyalev, has shown promise in a 12-month analysis. The data, which…
AbbVie's ROSSINI (NCT06107426) study of its Parkinson's disease combination, Vyalev, has shown promise in a 12-month analysis. The data, which…
On June 29, at the 12th Congress of the European Academy of Neurology (EAN) 2026, NeuroDerm presented post hoc analysis…
A systematic review and meta-analysis evaluating whether using Daiichi Sankyo’s Radicava (edaravone) and Sanofi’s Rilutek (riluzole) in combination provides additional…
Regeneron's Phase III generalised myasthenia gravis (gMG) trial shows high disease control potential of cemdisiran. The Phase III NIMBLE study…
Real-world treatment satisfaction and quality of life (QoL) of patients treated with TG Therapeutics’ Briumvi (ublituximab) for relapsing multiple sclerosis…
Sanofi/Ad Scientiam presented an interim analysis from the ongoing MS-DETECT (NCT05816122) study, showing that Microsoft (MS) Copilot can monitor disease…
Post hoc analysis shows that local inflammatory lesions associated with treatment with Sanofi's Cenrifki (tolebrutinib) in patients with multiple sclerosis…
Glomerulonephritides are conditions in which the primary renal filters (glomeruli) are inflamed, leading to scarring and reduced function. Glomerulonephritides can…
Cervical cancer can cause death but can be prevented with the human papillomavirus (HPV) vaccine. A recent study in England…
Uveitis is the leading cause of preventable blindness in adults aged 20–60 years, and while some details are known about…